EFG Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

EFG Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$927K	Sell	2,366 -8,838	-79%	-$3.69M	0.12%	165
2025 Q2	$4.99M	Buy	11,204 +2,072	+23%	+$955K	0.7%	46
2025 Q1	$4.43M	Sell	9,132 -2,923	-24%	-$1.36M	0.74%	37
2024 Q4	$4.86M	Buy	12,055 +3,964	+49%	+$1.84M	0.66%	42
2024 Q3	$3.76M	Sell	8,091 -348	-4%	-$167K	0.63%	38
2024 Q2	$3.95M	Buy	8,439 +1,138	+16%	+$494K	0.69%	35
2024 Q1	$3.05M	Sell	7,301 -39	-0.5%	-$16.5K	0.53%	61
2023 Q4	$2.99M	Buy	7,340 +2,502	+52%	+$924K	0.57%	65
2023 Q3	$1.68M	Sell	4,838 -186	-4%	-$65.1K	0.4%	87
2023 Q2	$1.77M	Buy	5,024 +722	+17%	+$243K	0.38%	89
2023 Q1	$1.35M	Sell	4,302 -113	-3%	-$33.9K	0.3%	119
2022 Q4	$1.28M	Buy	4,415 +451	+11%	+$137K	0.29%	127
2022 Q3	$1.15M	Buy	3,964 +951	+32%	+$274K	0.27%	128
2022 Q2	$849K	Buy	+3,013	New	+$806K	0.18%	159

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

EFG Asset Management's VRTX Position: Q3 2025 in Review

EFG Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 79% in Q3 2025, selling an estimated $3.69M and leaving 2,366 shares worth $927K. The position accounts for 0.12% of the portfolio, ranked #165.

EFG Asset Management first reported a position in VRTX in Q2 2022 and has held it in 14 quarters since. The position peaked at $4.99M in Q2 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

EFG Asset Management held 2,366 shares of Vertex Pharmaceuticals worth $927K as of Q3 2025.
EFG Asset Management sold 8,838 Vertex Pharmaceuticals shares in Q3 2025, an estimated $3.69M.
Vertex Pharmaceuticals made up 0.12% of EFG Asset Management's portfolio in Q3 2025, its #165 holding.
EFG Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
EFG Asset Management's Vertex Pharmaceuticals position peaked at $4.99M in Q2 2025.
1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on EFG Asset Management's 13F filing for Q3 2025, filed 3 Nov 2025.